Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

September 6, 2017

Primary Completion Date

May 22, 2019

Study Completion Date

June 30, 2020

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Proxalutamide

Stage1:Dose esclation. Stage2:the expansion cohort where one or no DLT takes place in planned study cohort.

Trial Locations (7)

100142

Beijing Cancer Hospital, Beijing

Unknown

Sun-Yat-sen University Cancer center, Guangzhou

The Fourth Hospital of Hebei Medical University, Shijiazhuang

Hunan Cancer Hospital, Changsha

Jiangsu Province Hospital, Nanjing

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

Tianjin Medical University Cancer Institute and Hospital, Tianjin

All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

collaborator

Tianjin Medical University Cancer Institute and Hospital

OTHER

collaborator

Sun Yat-sen University

OTHER

collaborator

Ruijin Hospital

OTHER

collaborator

The First Affiliated Hospital with Nanjing Medical University

OTHER

collaborator

Hebei Medical University Fourth Hospital

OTHER

collaborator

Hunan Cancer Hospital

OTHER

lead

Suzhou Kintor Pharmaceutical Inc,

INDUSTRY

NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter